Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
4.750
+0.099 (2.13%)
Feb 6, 2026, 4:00 PM EST - Market closed
Rallybio Revenue
Rallybio had revenue of $212.00K in the quarter ending September 30, 2025, a decrease of -29.10%. This brings the company's revenue in the last twelve months to $674.00K, up 12.71% year-over-year. In the year 2024, Rallybio had annual revenue of $636.00K.
Revenue (ttm)
$674.00K
Revenue Growth
+12.71%
P/S Ratio
39.50
Revenue / Employee
$44,933
Employees
15
Market Cap
25.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 636.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 8.85M |
| Evaxion | 7.65M |
| IGC Pharma | 1.11M |
| Serina Therapeutics | 116.00K |
| Daré Bioscience | -57.13K |
RLYB News
- 4 days ago - Rallybio Announces Reverse Stock Split of Common Stock - Business Wire
- 3 months ago - Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 4 months ago - Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
- 5 months ago - Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program - Business Wire
- 6 months ago - Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 7 months ago - Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
- 7 months ago - Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - Business Wire
- 8 months ago - Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire